cerelume

Evidence · Presentations and publications

Presented at ESMO and MAP. Under journal review.

MethyGlio, our cfDNA methylation liquid biopsy for glioma, has been presented to the field in oral presentations at ESMO and MAP congresses. The full manuscript is under journal review and is not yet published. This page sets out what has been presented, what is under review, and the peer-reviewed glioma work it builds on.

Oral and poster presentations

The MethyGlio evidence, presented to the field.

What has been presented

The atlas, the classifier and the first blood-based signatures.

  • MAP Congress 2026, invited oral. The 15,606-sample harmonised atlas, the 57,425 CpG sites shared across array generations, and the six nested classification tasks from tumour detection to molecular class.
  • ESMO Congress 2025, oral. DNA methylation-based epigenetic signatures for classification and non-invasive diagnosis of glioma.
  • MAP Congress 2025, oral. The Transformer framework for glioma classification and non-invasive diagnosis.
  • ESMO AI and Digital Oncology 2025, poster. Interpretable deep learning for glioma classification and liquid biopsy biomarker discovery.

The MethyGlio study · manuscript under peer review

The full MethyGlio manuscript, not yet published.

  • Atlas and model. A harmonised atlas of 15,606 methylation profiles and a hierarchical Transformer model, with 99.2% glioma subtype accuracy under locked, leakage-controlled evaluation.
  • Independent clinical evaluation. In an independent cohort of 68 consecutively enrolled neurosurgical patients, the locked model, with no retraining, achieved an AUC of 0.958 for tumour entity (61 evaluable patients) and, among the 27 glioma samples, 0.955 for subtype, 0.953 for grade and 0.903 for molecular class.
  • Circulating biomarker discovery. Candidate cfDNA methylation markers, with proof-of-concept serum-to-tumour concordance at selected loci in a small number of matched cases. Larger prospective blood-based studies are required.
  • Status. The manuscript has not yet completed peer review, so these results are data on file. MethyGlio is research-stage and is not approved for clinical diagnosis.

Oral presentations

  1. Invited oral

    MethyGlio: a 15,606-sample methylation atlas supporting six clinically aligned decisions

    MAP Congress 2026 (Molecular Analysis for Precision Oncology) · London, United Kingdom · 10 to 11 September 2026

  2. Oral · ESMO Merit Award

    DNA methylation-based epigenetic signatures for classification and non-invasive diagnosis of gliomas

    ESMO Congress 2025 · Berlin, Germany · 20 October 2025

  3. Oral · MAP Merit Travel Grant

    DNA methylation-based epigenetic signatures for glioma classification and non-invasive diagnosis: a Transformer framework integrating cachexia risk assessment

    MAP Congress 2025 · Paris, France · 15 to 16 September 2025

Poster presentations

  1. Poster · ESMO AI Merit Travel Grant

    DNA methylation profiling with interpretable deep learning for glioma classification and liquid biopsy biomarker discovery

    ESMO AI and Digital Oncology Congress 2025, poster 38P · Berlin, Germany · 30 September to 1 October 2025

  2. Poster · ESMO Merit Travel Grant

    Large-scale genome-wide association study and fine mapping uncover key genetic loci and credible genes of glioma

    ESMO Congress 2025, poster 2115 · Berlin, Germany · 17 to 21 October 2025

  3. Poster

    Genome-wide association study and fine mapping uncover novel genetic loci and credible genes of glioma

    ESMO AI and Digital Oncology Congress 2025, poster 12P · Berlin, Germany · 30 September to 1 October 2025

  4. Poster

    Genome-wide association study and fine mapping uncover novel genetic loci and credible genes of glioma

    MAP Congress 2025, poster 213 · Paris, France · 15 to 16 September 2025

  5. Poster · Cancer Cachexia Society Best Poster Award

    DNA methylation-based epigenetic signatures for glioma classification and non-invasive diagnosis: a Transformer framework integrating cachexia risk assessment

    8th Cancer Cachexia Conference · Turin, Italy · 25 to 27 September 2025

Ten national oral presentations in China between 2021 and 2025, including the Chinese Medical Association Neurosurgery Branch annual meetings (Kunming 2024, Suzhou 2025), the Chinese Neurosurgical Society (Haikou 2023), the Chinese Medical Doctor Association Neurosurgery Branch (Xiamen 2024) and the Chinese Society for Neuroscience Neuro-Oncology Conference (Changchun 2025).

Peer-reviewed publications

The published glioma work it builds on.

These papers are tissue-based studies of glioma biology, methylation and prognosis. They are the foundation for MethyGlio rather than liquid biopsy studies themselves.

Featured, open access · glioma biology and methylation

First page of Modification patterns of DNA methylation-related lncRNAs regulating genomic instability for improving clinical outcomes and tumour microenvironment characterisation of lower-grade gliomas

Frontiers in Molecular Biosciences · 2022

Modification patterns of DNA methylation-related lncRNAs regulating genomic instability for improving clinical outcomes and tumour microenvironment characterisation of lower-grade gliomas

first authorRead ↗

First page of N7-methylguanosine regulator-mediated methylation modification patterns and characterisation of the immune microenvironment in lower-grade glioma

European Journal of Medical Research · 2023

N7-methylguanosine regulator-mediated methylation modification patterns and characterisation of the immune microenvironment in lower-grade glioma

first authorRead ↗

First page of Identification and validation of a novel eight mutant-derived lncRNA signature as a prognostic biomarker for genome instability in low-grade glioma

Aging · 2021

Identification and validation of a novel eight mutant-derived lncRNA signature as a prognostic biomarker for genome instability in low-grade glioma

first authorRead ↗

First page of CRISPR-Cas9 screening identified lethal genes enriched in the Hippo kinase pathway and of predictive significance in primary low-grade glioma

Molecular Medicine · 2023

CRISPR-Cas9 screening identified lethal genes enriched in the Hippo kinase pathway and of predictive significance in primary low-grade glioma

co-first authorRead ↗

First page of Integrated machine learning survival framework based on mitochondrial function and cell death patterns in a large multicentre cohort for lower-grade glioma

Journal of Translational Medicine · 2023

Integrated machine learning survival framework based on mitochondrial function and cell death patterns in a large multicentre cohort for lower-grade glioma

co-first authorRead ↗

Other relevant publications

18 peer-reviewed papers, 2021 to 2026

  1. 2026co-author
  2. 2026

    Genome-wide association study identifies novel pleiotropic loci linking glioma susceptibility to systemic metabolic traits and vascular-glial-immune annotations

    Molecular Therapy

    co-author
  3. 2025first author
  4. 2025second author
  5. 2024first author
  6. 2024co-first author
  7. 2023first author
  8. 2023first author
  9. 2023first author
  10. 2023co-first author
  11. 2023co-first author
  12. 2022first author
  13. 2022first author
  14. 2022first author
  15. 2022co-author
  16. 2021first author
  17. 2021first author
  18. 2021first author

Collaborate with Cerelume

Help bring a clearer signal to brain tumour care.

Start a conversation

References

  1. 1Maimaiti A. MethyGlio: a 15,606-sample methylation atlas supporting six clinically aligned decisions. Invited oral presentation, MAP Congress 2026, London; 10 to 11 September 2026.
  2. 2Maimaiti A, et al. MethyGlio: cfDNA methylation and liquid biopsy for glioma classification. Manuscript under journal review. Data on file, Cerelume; 2026.
  3. 3ORCID record for Aierpati Maimaiti, 0000-0002-6876-3165, and Semantic Scholar author record (h-index). Accessed September 2026. orcid.org/0000-0002-6876-3165

Publication details are from Crossref and the ORCID record, and each listed paper links to its DOI. Presentation details are from the authors' conference record. Faces of other delegates in the congress photograph have been blurred.